To examine ischemic tolerance in the absence of A1 adenosine receptors (A1ARs), isolated wild-type (WT) and A1AR knockout (A1KO) murine hearts underwent global ischemia-reperfusion, and injury was measured in terms of functional recovery and efflux of lactate dehydrogenase (LDH). Hearts were analyzed by real-time RT-PCR both at baseline and at intervals during ischemia-reperfusion to determine whether compensatory expression of other adenosine receptor subtypes occurs with either A1AR deletion and/or ischemia-reperfusion. A1KO hearts had higher baseline coronary flow (CF) and left ventricular developed pressure (LVDP) than WT hearts, whereas heart rate was unchanged by A1AR deletion. After 20 min of ischemia, CF was attenuated in A 1KO compared with WT hearts, and this reduction persisted throughout reperfusion. Final recovery of LVDP was decreased in A1KO hearts (54.4 Ϯ 5.1 vs. WT 81.1 Ϯ 3.4% preischemic baseline) and correlated with higher diastolic pressure during reperfusion. Postischemic efflux of LDH was greater in A 1KO compared with WT hearts. Real-time RT-PCR demonstrated the absence of A 1AR transcript in A1KO hearts, and the message for A2A, A2B, and A3 adenosine receptors was similar in uninstrumented A1KO and WT hearts. Ischemia-reperfusion increased A 2B mRNA expression 2.5-fold in both WT and A1KO hearts without changing A1 or A3 expression. In WT hearts, ischemia transiently doubled A2A mRNA, which returned to preischemic level upon reperfusion, a pattern not observed in A 1KO hearts. Together, these data affirm the cardioprotective role of A1ARs and suggest that induced expression of other adenosine receptor subtypes may participate in the response to ischemia-reperfusion in isolated murine hearts. gene expression; coronary flow; lactate dehydrogenase ADENOSINE HAS BROAD cardiovascular effects, including the ability to protect the heart from ischemia-reperfusion injury. Interacting with its four known receptor subtypes (A 1 , A 2A , A 2B , and A 3 receptors), adenosine serves as a homeostatic autacoid to moderate ischemia-induced imbalances of metabolic supply and demand (4, 7, 17, 33) . A 1 adenosine receptor (A 1 AR) activation figures prominently in adenosinergic cardioprotection (7, 17, 24, (33) (34) (35) 48) in part through negative chronotropic, dromotropic, and inotropic responses as well as protective antiadrenergic effects (4, 7), and it plays a central role in the powerfully cardioprotective adaptation of ischemic preconditioning (14, 21, 28, 30) . For these reasons, considerable attention is given to exploring the therapeutic potential of adenosine in an effort to harness its intrinsic benefits in the management of ischemic heart disease (reviewed in Ref. 13 and 37).
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Although the bulk of adenosine-mediated protection against ischemia-reperfusion occurs through activation of A 1 ARs, it is becoming clear that other adenosine receptor subtypes contribute to this response. For instance, there is evidence that A 2A receptor activation reduces infarct size and attenuates postischemic myocardial stunning both selectively with CGS-21680 (5, 25) and nonselectively with the mixed A 1 /A 2A agonist AMP-579 (20, 21) . Likewise, A 3 receptor-mediated cardioprotection is observed with selective agonists in isolated hearts (36, 47) and through coactivation with A 1 ARs (using binary agonists) in cardiac myocytes (18) . Thus the apparent coregulatory roles of other adenosine receptor subtypes in response to myocardial ischemia-reperfusion are being gradually advanced by a traditional pharmacological approach. However, the advent of gene-modified animal models with either transgenic overexpression (6, 29) or targeted deletion (26, 39, 42) of adenosine receptor subtypes, in concert with ever-improving pharmacological specificity, now allows for highly selective experimental strategies aimed at better understanding the receptor-specific cardiovascular effects of adenosine (6, 15, 29 -32, 42-46) . Indeed, with the use of this combined approach, data from the A 1 knockout (A 1 KO) model recently developed by Sun et al. (42) affirm a protective role of A 1 AR activation in renal ischemia-reperfusion (27) , but the effects of A 1 deletion on the heart and vasculature are only beginning to be characterized (23, 38, 45, 46) . Moreover, the appropriate interpretation of data from studies using these models requires a determined effort to evaluate in parallel the phenotypic, and potentially unanticipated genotypic, alterations that may occur as a consequence of targeted genetic manipulation (1, 11, 22) ; that is, the functional genomics of gene-modified models must be assessed, preferably within the context of conditional settings of interest, e.g., ischemia-reperfusion, to optimize the insight gained by using them.
Therefore, we sought to examine the effects of targeted gene deletion of A 1 adenosine receptors on the myocardial response to ischemia-reperfusion and to evaluate baseline and postischemic expression of adenosine receptor subtypes in isolated wild-type (WT) and A 1 KO mouse hearts. We hypothesized that tolerance to ischemia-reperfusion would be impaired in A 1 KO hearts and that the expression of other adenosine receptor subtypes would demonstrate compensatory changes either at baseline or by induction through ischemia-reperfusion.
MATERIALS AND METHODS
Animals. All animals were cared for in accordance with a protocol approved by the Animal Care and Use Committee of the Brody School of Medicine at East Carolina University. A 1KO mice and their respective WT littermate controls were obtained from a subcolony of the original lines generated by Sun et al. (42) on a background strain mix of 129Sv/J and c57BL/6. Colonies of WT and A 1KO mice were bred on site at the Brody School of Medicine, and genotype status was verified by tail-snip PCR. All animals used in a given experiment originated from the same breeding series and were matched for age and weight. Both male and female mice were used, and the representation of each sex was equal within all experimental groups. Standard laboratory food and water were available ad libitum. Housing temperature was held constant at 23 Ϯ 2°C, humidity was 60 Ϯ 10%, and an inverted 12-h:12:h light-dark cycle was used (lights off at 1900). All animal procedures conformed to the Guide for the Care and Use of Laboratory Animals, published by the National Institutes of Health (Publication No. 85-25, Revised 1996) .
Langendorff isolated heart model. Isolated heart experiments were performed as previously described (30 -32, 43, 44, 46) , using a murine model that has been fully characterized (16, 17) . Animals were anesthetized with intraperitoneal pentobarbital sodium (50 mg/kg), a thoracotomy was performed, and the hearts were excised into ice-cold heparinized (5 U/ml) perfusate. After the removal of lung and surrounding tissue, the aorta was rapidly cannulated with a 20-gauge, blunt-ended needle, and retrograde coronary perfusion was initiated at a constant pressure of 80 mmHg with modified Krebs-Henseleit buffer containing (in mM) 120 NaCl, 25 NaHCO 3, 4.7 KCl, 1.2 KH2PO4, 2.5 CaCl 2, 1.2 MgSO4, 15 glucose, and 0.05 EDTA. The perfusate was equilibrated with 95% O 2-5% CO2 at 37°C, giving a pH of 7.4 and PO 2 of ϳ550 mmHg. The left atrium was removed, and the left ventricle was vented with a small polyethylene apical drain. A fluid-filled balloon constructed of plastic film was inserted into the left ventricle across the mitral valve and connected to a pressure transducer, permitting continuous measurement of left ventricular pressure. Balloon volume was modified through a stopcock attached to the ventricular pressure transducer using a 500-l glass syringe (Hamilton; Reno, NV) to maintain a left ventricular diastolic pressure of 2-5 mmHg. Tungsten wires were connected to the stainless steel cannula and through the apical myocardium for pacing during reperfusion. Hearts were immersed in a water-jacketed perfusate bath maintained at 37°C, and the bath was rinsed once at the onset of perfusion to clear blood from the bathing environment. Coronary flow was continuously monitored via a Doppler flow probe (Transonic Systems; Ithaca, NY) located in the aortic perfusion line. Coronary flow, aortic pressure, and left ventricular pressure were all recorded on a PowerLab multichannel data acquisition system (ADInstruments; Castle Hill, Australia) connected to a MacIntosh G4 computer. The ventricular pressure signal was digitally processed (using PowerLab Chart software version 5.0.1, ADInstruments) to yield diastolic and systolic pressures, heart rate, and positive and negative first derivative of pressure (ϩdP/dt and ϪdP/dt, respectively).
Ischemia-reperfusion protocol. All hearts were equilibrated for 30 min before ischemia-reperfusion. Coronary flow, heart rate, developed pressure (systolic pressure Ϫ diastolic pressure), ϩdP/dt, and ϪdP/dt were continuously measured in WT and A 1KO hearts, and baseline data for these parameters were sampled at the end of equilibration.
After equilibration, hearts underwent 20 min of global normothermic ischemia, followed by 40 min of reperfusion. Global ischemia was produced by clamping the aortic cannula inflow and simultaneously bubbling 95% N 2-5% CO2 through the organ bath to reduce ambient PO 2. Reperfusion was achieved by unclamping the aortic inflow and discontinuing the nitrogen bubbling. Hearts were paced at 7 Hz throughout reperfusion beginning 90 s after unclamping the aortic inflow (16, 30) with the use of a Grass S6 stimulator (Grass Instruments; Quincy, MA) with 2-ms square-wave pulses at 20% above threshold (usually 3-6 V). Functional performance was continuously recorded throughout the ischemia-reperfusion protocol, and data for coronary flow, heart rate, diastolic pressure, developed pressure, and ϮdP/dt were sampled at 1, 3, and 5 min and at 5-min intervals thereafter during both ischemia and reperfusion. At the end of reperfusion, hearts were weighed and flash frozen at Ϫ80°C for determination of adenosine receptor mRNA expression by real-time RT-PCR.
Coronary efflux of lactate dehydrogenase. The content of lactate dehydrogenase (LDH) within the coronary venous effluent was examined as a biochemical marker of cardiomyocyte injury. For each heart, a baseline sample of coronary effluent was collected from the superfusate bath overflow during the last minute of equilibration (before the onset of global ischemia). Coronary effluent was then continuously collected throughout the entire reperfusion period. LDH determination was performed using an automated spectrophotometric clinical assay using an ACE Chemistry Analyzer (Alfa Wassermann; West Caldwell, NJ). The total volume of coronary efflux during ischemia-reperfusion was measured at the end of reperfusion, and a 1.5-ml aliquot was stored on ice for assay within 24 h of the experiment. Total efflux of LDH was normalized to wet weight of the heart (in U/g).
Adenosine receptor expression. To determine whether targeted deletion of A 1ARs induces compensatory changes in expression of other adenosine receptor subtypes, real-time RT-PCR was performed on uninstrumented hearts (not cannulated or perfused with the Langendorff apparatus) from WT and A1KO mice. Hearts in this subset were extracted, and extraneous tissue was removed, rinsed of blood (using modified Krebs buffer), and flash frozen at Ϫ80°C pending analysis of adenosine receptor expression. To determine whether the relative expression of each receptor subtype is altered during ischemia-reperfusion, real-time RT-PCR was performed on subsets of isolated WT and A1KO hearts. Isolated heart experiments were performed as described above, but the ischemia-reperfusion protocol was interrupted at three time points: 1) at the end of equilibration (before ischemia), 2) at the end of ischemia (before reperfusion), and 3) at the end of reperfusion. WT and A1KO hearts from each of these time points were removed from the Langendorff apparatus and flash frozen at Ϫ80°C pending analysis of adenosine receptor expression.
Whole hearts were homogenized in 3 ml TRIzol reagent (GIBCO, Gaithersburg, MD), and total RNA was isolated according to the manufacturer's instructions and treated with DNase to remove contamination of DNA. Real-time quantitative RT-PCR was performed in duplicate on a Bio-Rad iCycler Real-Time Detection System (BioRad, Hercules, CA). PCR reactions used the Superscript III one-step RT-PCR system with Platinum Taq DNA Polymerase (Invitrogen, Carlsbad, CA). The adenosine receptor primers, probe sequences, and reaction protocols used were similar to previously reported methods (2) . Primer pairs for all adenosine receptor subtypes were purchased from Invitrogen, and specific probes for each of the receptor subtypes were obtained from Applied Biosystem (Foster City, CA). The reaction mixture contained (in l) 12.5 2ϫ reaction mix, 1 forward primer, 1 reverse primer, 1 probe (FAM-MGB labeled), 1 SuperScript III, 1 total RNA (500 ng), and 6.4 MgCl (50 mM), and water was added to total volume of 25 l. Fluorescent dye SYBR Green I (Bio-Rad) was used for ␤-actin quantitation as an internal control (no differences in postischemic expression were observed using either ␤-actin or 18S RNA as internal controls; data not shown). ␤-Actin oligonucleotide primers were also purchased from Invitrogen and had the following configurations: forward 5Ј-ACC-AAC-TGG-GAC-GAT-ATG-GAG-AAG-A-3Ј; reverse 5Ј-TAC-GAC-CAG-AGG-CAT-ACA-GGG-ACA-A-3Ј (38) . For ␤-actin quantitation, the reaction mixture used was the same as described above, except 1 l SYBR Green I was used instead of probes and 10 ng of total RNA were used instead of 500 ng. The RT-PCR reaction consisted of an initial step of 30 min at 50°C (cDNA synthesis) and then 95°C for 15 min (denaturation and inactivation of reverse transcriptase enzyme). This was followed by 40 cycles consisting of 15 s at 95°C and 1 min at 60°C. Gene expression for each adenosine receptor subtype was normalized to ␤-actin as the internal control (adenosine receptor expression-to-␤-actin expression within sample ratio ϫ 100).
Statistical analysis. Unpaired Student's t-tests were used to compare baseline functional data and coronary efflux of LDH between WT and A 1KO groups. Functional parameters during ischemia-reperfusion were analyzed by two-way repeated-measures ANOVA, applying StudentNewman-Keuls post hoc test for multiple pairwise comparisons. For isolated hearts, differences in adenosine receptor expression between WT and A 1KO groups were analyzed by using two-way ANOVA with Student-Newman-Keuls post hoc test for multiple comparisons. Exact Wilcoxon tests were used to detect differences of adenosine receptor expression between uninstrumented hearts and isolated hearts at the end of equilibration. For all tests, a P value of Ͻ0.05 was considered statistically significant. Table 1 summarizes functional parameters after 30 min of equilibration in isolated murine hearts perfused at constant pressure under normothermic aerobic conditions. The average body weight, heart weight, heart-to-body weight ratio, and spontaneous heart rate were similar in WT and A 1 KO hearts. Baseline functional parameters for both WT and A 1 KO hearts were within the range of previously reported values from isovolumically contracting isolated murine hearts (16, 31, 35) ; however, coronary flow, developed pressure, ϩdP/dt, and ϪdP/dt were all greater in A 1 KO than in WT hearts (Table 1) .
RESULTS

Baseline function in isolated WT and A 1 KO hearts.
Functional effects of ischemia-reperfusion. Myocardial function (expressed as the percent change from baseline developed pressure) during ischemia-reperfusion is shown in Fig.  1A . Upon interruption of coronary flow at time 0 (Fig. 1B) , all hearts demonstrated a rapid loss of developed pressure and complete asystole within 2-3 min (Fig. 1A) . Hearts remained nonfunctional through the 20-min ischemic event, and diastolic pressure rose steadily between 3 and 15 min, indicating the development of ischemic contracture (Fig. 1C) . The onset of ischemic contracture, defined as the time to 20% maximum contracture (16) , occurred earlier in A 1 KO hearts than in WT hearts (282 Ϯ 13.1 and 322 Ϯ 10.4 s, respectively; n ϭ 13 both groups, P Ͻ 0.05), as illustrated by a significantly higher diastolic pressure at 5 min in A 1 KO hearts (Fig. 1C) .
With the onset of reperfusion (at time 20) , all hearts recovered coronary flow (Fig. 1B) and developed pressure (Fig. 1A) and demonstrated a rapid decrease in diastolic pressure (Fig.  1C) , although these responses differed between WT and A 1 KO hearts. Although WT hearts demonstrated an immediate postis- chemic coronary vasodilation to 156 Ϯ 8.4% of preischemic values, this response was absent in A 1 KO hearts (104.4 Ϯ 8.2%; n ϭ 8 both groups, P Ͻ 0.05), and coronary flow remained approximately one-third lower in A 1 KO hearts for the duration of reperfusion (Fig. 1B) . Likewise, immediate recovery of developed pressure in A 1 KO hearts was lower than that of WT hearts (58.5 Ϯ 8.9 and 95.7 Ϯ 8.9% of baseline, respectively, at 1 min; n ϭ 8 both groups, P Ͻ 0.05), and this poorer functional recovery was maintained from 5 min to the end of reperfusion (Fig. 1A) . (Fig. 1C) .
Coronary efflux of LDH. The concentration of LDH in the coronary effluent before and after ischemia is represented in Fig. 2 . Preischemic release of LDH was minimal for both WT and A 1 KO groups (3.8 Ϯ 0.09 and 4.0 Ϯ 0.7 U/g, respectively; n ϭ 8 both groups; NS) and was comparable with previous reports (16) . Ischemia-reperfusion resulted in increased coronary efflux of LDH in both groups (Fig. 2) ; however, the concentration was significantly higher in A 1 KO than in WT hearts (45.5 Ϯ 6.9 and 25.0 Ϯ 1.2 U/g, respectively; n ϭ 8 both groups; P Ͻ 0.05). As a marker of cellular injury, the greater postischemic efflux of LDH in A 1 KO hearts correlated with impaired functional recovery compared with WT hearts (Figs.  1A and 2) .
Adenosine receptor expression. Relative quantitation of adenosine receptor mRNA by real-time PCR demonstrated the absence of A 1 adenosine receptor expression in both uninstrumented (Fig. 3) and isolated A 1 KO hearts (Fig. 4A) . In uninstrumented WT hearts, mRNA expression was highest for A 1 and and A 2A adenosine receptors with approximately two-to threefold lower message for A 2B and A 3 receptors. Targeted deletion of the A 1 receptor resulted in no compensatory changes in A 2A , A 2B , or A 3 adenosine receptors in A 1 KO compared with WT hearts (Fig. 3) . Although A 1 AR mRNA in isolated WT hearts was reduced at the end of equilibration compared with uninstrumented hearts (2.35 Ϯ 0.43 vs. 4.15 Ϯ 0.75% ␤-actin, respectively; P Ͻ 0.05; Figs. 3 and 4A) , ischemia-reperfusion did not affect A 1 AR expression (Fig. 4A) .
In isolated WT hearts, A 2A receptor mRNA was reduced at the end of equilibration compared with uninstrumented hearts (2.20 Ϯ 0.21 vs. 6.42 Ϯ 1.40% ␤-actin, respectively; P Ͻ 0.05), but no decrease in A 2A expression was observed between isolated and uninstrumented A 1 KO hearts (4.09 Ϯ 0.66 vs. 7.03 Ϯ 1.48% ␤-actin, respectively; NS; Figs. 3 and 4B) . A 2A adenosine receptor mRNA increased immediately after ischemia in WT hearts compared with the end of equilibration within this group; however, A 2A transcript level was unchanged by ischemia-reperfusion in the A 1 KO hearts (Fig. 4B) . This upregulation of A 2A receptor expression in WT hearts at the end of ischemia returned to preischemic levels after reperfusion (Fig. 4B) .
As observed for the expression of A 1 and A 2A receptors, A 2B mRNA in isolated WT hearts appeared lower at the end of equilibration compared with uninstrumented hearts but narrowly failed to meet statistical significance (1.24 Ϯ 0.19 vs. 2.42 Ϯ 0.50% ␤-actin, respectively; P ϭ 0.055). A 2B expression was lower in isolated versus uninstrumented A 1 KO hearts (1.69 Ϯ 0.34 vs. 2.78 Ϯ 0.43% ␤-actin, respectively; P Ͻ 0.05; Figs. 3 and 4C ). When compared with the end of equilibration, A 2B adenosine receptor expression increased 2.5-fold after ischemia-reperfusion in both WT and A 1 KO hearts (Fig. 4C) . Moreover, this increase in A 2B receptor mRNA was evident only after reperfusion and not at the end of ischemia (Fig. 4C) . A 3 adenosine receptor transcript levels were not different between WT and A 1 KO hearts at each time point examined and were unchanged by ischemia-reperfusion (Fig. 4D) .
DISCUSSION
The dual purpose of this study was to examine the tolerance to ischemia-reperfusion in isolated A 1 KO mouse hearts and to determine whether targeted deletion of A 1 adenosine receptors alters the expression of other adenosine receptor subtypes either under basal conditions or by induction through ischemia-reperfusion. Baseline contractile function and coronary flow were enhanced in A 1 KO hearts (compared with WT hearts) during normoxic constant pressure perfusion. A 1 KO hearts demonstrated impaired tolerance to ischemia-reperfusion as evidenced by poorer postischemic recovery of contractile function, decreased coronary vasodilation in Fig. 2 . Concentration of lactate dehydrogenase (LDH) released in coronary effluent from isolated WT (n ϭ 8) and A1KO (n ϭ 8) hearts during ischemiareperfusion. Values represent means Ϯ SE. *Significant differences compared with preischemic concentration within group; #significant difference between WT and A1KO groups, P Ͻ 0.05. Fig. 3 . Adenosine receptor mRNA determined by real-time RT-PCR in uninstrumented WT and A1KO hearts (n ϭ 4 for both groups). Values represent means Ϯ SE normalized to %␤-actin from whole heart homogenates. *Significant difference between WT and A1KO groups, P Ͻ 0.05.
reperfusion, and increased tissue injury compared with WT hearts. In uninstrumented WT hearts, receptor expression was highest for A 1 and A 2A adenosine receptors with two-to threefold lower levels of A 2B and A 3 mRNA, and targeted deletion of A 1 adenosine receptors had no effect on cardiac expression of other adenosine receptor subtypes in A 1 KO hearts. In isolated WT hearts, A 2A adenosine receptor mRNA transiently increased immediately after ischemia, returning to the preischemic level by the end of reperfusion. After ischemia-reperfusion, there was a 2.5-fold increase in A 2B adenosine receptor transcript in both WT and A 1 KO hearts. Taken together, these data affirm the cardioprotective role of A 1 adenosine receptors and suggest that induced expression of other adenosine receptor subtypes may participate in the response to ischemia-reperfusion in isolated murine hearts.
Adding to the long-standing recognition that A 1 AR activation plays a predominant role in protecting the heart from ischemia-reperfusion (7, 13, 24, 35, 37, 48) , an expanding body of evidence points to coregulatory involvement of other adenosine receptor subtypes in modifying response(s) to myocardial injury (5, 17, 18, 20, 21, 25, 33, 36, 47) . Much of this evidence derives from an increasing array of selective and nonselective adenosine analogs aimed at discerning the cardioprotective contributions of A 2A (5, 20, 21, 25) and A 3 (18, 36, 47) adenosine receptors across a variety of in vivo, isolated heart and cultured myocyte models from a number of different species (5, 18, 20, 21, 25, 36, 47) . Development of selective and potent ligands for the A 2B adenosine receptor lags behind that of the other subtypes (8) , leaving a paucity of data as to whether A 2B receptors modify the cardiac response to ischemia-reperfusion. Thus, although the traditional pharmacological approach yields important data, it is a method with limitations for which gene-modified models of targeted adenosine receptor overexpression (6, 29) and deletion (26, 39, 42) are proving invaluable adjuncts in characterizing the cardiovascular effects of each adenosine receptor subtype. We have successfully applied this combined strategy to examine receptorspecific coronary and aortic vascular responses to adenosine and its pharmacological analogs in A 1 (45, 46) , A 2A (31, 44) , and A 3 (43) adenosine receptor knockout models and have begun to integrate it in assessing the consequences of ischemia-reperfusion in isolated mouse hearts (32) .
Effects of A 1 AR deletion on baseline cardiac function. The current observation that baseline heart rate was indistinguishable between A 1 KO and WT hearts is consistent with the initial in vivo characterization of this model (42) , as well as recent reports in isolated A 1 KO hearts (38, 46) . It is interesting to note, however, that the similar basal heart rate in A 1 KO and WT hearts contrasts with the observation of lower heart rates both in vivo (11) and in isolated hearts (11, 29, 30 ) from transgenic animals with cardiac-specific A 1 adenosine receptor overexpression (compared to heart rates of their WT littermates). The absence of a functional A 1 -mediated negative chronotropic response in A 1 KO hearts is evidenced by the inability to elicit bradycardia with the selective A 1 agonist 2-chloro-N 6 -cyclopentyladenosine in isolated hearts (10 M, unpublished observations from our laboratory) or with Ncyclohexyladenosine in vivo (42) . The current findings in A 1 KO hearts, along with previous observations in transgenic hearts overexpressing A 1 ARs, indicate that although endogenous activation of A 1 ARs occurs under basal (normoxic) conditions, the effect on heart rate is negligible in WT hearts but Fig. 4 . Relative expression of receptor mRNA determined by real-time RT-PCR for A1 (A), A2A (B), A2B (C), and A3 (D) adenosine receptors from isolated WT and A1KO hearts. Transcript expression is shown for isolated hearts interrupted at each of three key time points during the ischemia-reperfusion protocol: end equilibration (before ischemia), end ischemia (before reperfusion), and end reperfusion (n ϭ 7-8 at each time point for both groups). Values represent means Ϯ SE normalized to %␤-actin from whole heart homogenates. *Significant differences between WT and A1KO groups; #significant differences compared with end equilibration within group; †significant differences compared with end ischemia within group, P Ͻ 0.05. sufficient to modulate intrinsic rate in the setting of A 1 AR excess.
Targeted deletion of A 1 ARs resulted in higher baseline coronary flow, developed pressure, ϩdP/dt, and ϪdP/dt compared with WT hearts. These findings are consistent with recent data from Mustafa's laboratory (46) , demonstrating that acute selective A 1 antagonism with 1,3-dipropyl-8-cyclopentylxanthine enhances coronary dilation by adenosine and 5Ј-N-ethyl-carboxamidoadenosine in WT but not in A 1 KO hearts; that is, deletion of A 1 ARs eliminates an A 1 -mediated negative modulatory (vasoconstrictive) effect on coronary regulation by other adenosine receptor subtypes (A 2A and A 2B ) . The current data affirm our prior observation that baseline contractility is also enhanced in A 1 KO compared with WT hearts (46) . Our findings in unpaced hearts, however, contrast with those of Reichelt et al. (38) and Lankford et al. (23) , who noted similar coronary flow and contractility in isolated A 1 KO and WT hearts paced at either 420 or 480 beats/min. The causal relationship between higher coronary flow and greater contractile performance in A 1 KO hearts in the present study is not clear, yet these preischemic differences from WT hearts may have contributed to the increased susceptibility to ischemic injury in A 1 KO hearts.
Effects of A 1 AR deletion on ischemic tolerance. Tolerance to ischemia-reperfusion was impaired by targeted deletion of A 1 ARs, both from the standpoint of functional recovery and degree of tissue oncosis as determined by the concentration of LDH present in coronary effluent. These findings support the established cardioprotective role of A 1 ARs in ischemia-reperfusion (7, 17, 33) , whether it occurs by endogenous activation (35, 48) or exogenously through acute application of high-dose adenosine agonists (7, 24, 33) . The decreased tolerance to ischemia-reperfusion in A 1 KO hearts contrasts with enhanced ischemic tolerance in hearts overexpressing A 1 ARs (11, 22, 29, 30, 36) . In line with recent data (23, 38) , the nature of impaired postischemic function in A 1 KO hearts was multifaceted with lower initial and sustained developed pressure, lower initial and sustained coronary flow, and worsened diastolic dysfunction through all but the initial phase of reperfusion. The effective absence of reactive coronary vasodilation in A 1 KO hearts, followed by lower than preischemic coronary flow, correlated with diastolic failure during reperfusion (Fig. 1, B and C).
Our current demonstration of impaired ischemic tolerance with A 1 AR deletion contradicts data by Schulte et al. (41) in isolated hearts from an alternative (concomitantly developed) murine A 1 KO model (19) . They report abrogation of the infarct sparing effect of remote (cerebral) ischemic preconditioning in A 1 KO hearts, yet their data indicate postischemic functional tolerance was not altered by A 1 AR deletion (41) . The former finding is of interest in that it supports a role for A 1 ARs in mediating remote preconditioning; however, their latter finding conflicts not only with our current observations and those of Reichelt et al. (38) and Lankford et al. (23) but also with pharmacological data demonstrating that ischemic tolerance is limited by selective A 1 AR antagonism (24, 35, 48) . Indeed, we have previously demonstrated that acute pretreatment with DPCPX reduces postischemic contractile performance by 35% in isolated WT mouse hearts (30) . Although reasons for this discrepancy are not readily apparent, it is worth noting that the two A 1 KO lines differ with regard to background strain and structure of the mutated gene (19, 42 (1) have previously reported downregulation of A 1 AR transcript in isolated WT hearts after 30 min of ischemia-reperfusion; however, our data raise the possibility that even brief (3-5 min) cold ischemia, which necessarily occurs during dissection and cannulation of the mouse heart, may result in a similar decrease in A 1 AR mRNA. This unexpected observation warrants further examination to determine whether adenosine receptor protein expression is altered solely by isolating murine hearts. Although mRNA levels may not necessarily reflect actual protein expression (or functional G protein coupling), it is intriguing that at the end of equilibration A 2A mRNA was markedly lower in WT hearts, demonstrating lower baseline coronary flow, whereas coronary flow was greater in A 1 KO hearts expressing almost twice the A 2A mRNA. In our review of the literature, this represents the first parallel evaluation of the cardiac phenotype and genotypic adenosine receptor profile resulting from targeted deletion of an adenosine receptor subtype.
Ischemia-reperfusion induced a 2.5-fold induction of A 2B receptor transcript in both WT and A 1 KO hearts. This postischemic induction of A 2B receptor expression mirrors findings after hypoxia in human (umbilical vein) endothelial and (bronchial) smooth muscle cells (10) and is particularly interesting given the low affinity of this receptor subtype (8) and its purported role in modulating angiogenesis (9) . The induction of A 2B expression observed here also compares favorably with data from Ashton et al. (2) in a recent analysis of adenosine receptor transcription after ischemia-reperfusion in isolated murine hearts. The significance of induced A 2A receptor expression in WT hearts immediately after ischemia is also not clear, because this increase is not apparent after reperfusion. Nonetheless, the data affirm that ischemia-reperfusion alters the gene expression profile of adenosine receptor subtypes, the most dramatic of which, i.e., A 2B expression, is unaffected by targeted A 1 AR deletion. Given the important modulatory roles of adenosine receptors in inflammation, cardioprotection, and fibroblast growth, postischemic induction of adenosine receptors may have an important impact on the longer term response to ischemic insult. This warrants further investigation.
Study limitations. As with all studies using isolated heart preparations, consideration must be given to the fact that the functional and genotypic evaluation of A 1 KO hearts may be limited by the absence of humoral and/or cell-mediated factors that could modify the response to cardiac ischemia-reperfusion. However, this same limitation may be construed as a potential experimental advantage allowing extraction of the magnitude of these component factors in ischemic injury through a comparison with in vivo models of ischemia-reperfusion using adenosine receptor knockout mice. Importantly, mRNA expression of adenosine receptor subtypes may not actually reflect the relative patterns of protein expression (or G protein coupling), because the efficiency of translation and posttranslational modification and/or trafficking may alter the relationship between mRNA and individual proteins. Also, because the gene expression profile was performed by analysis of whole heart preparations, it is not possible to distinguish differences in adenosine receptor subtypes among cell populations existing therein, including cardiomyocytes, vascular cells, fibroblasts, and any resident inflammatory cells. Finally, a complete analysis of the potential impact of A 1 AR deletion on other relevant systems (e.g., ␤-adrenergic) has not been assessed but represents an important component of future work that is needed with this model.
Conclusions and future directions. Targeted deletion of A 1 ARs results in increased basal coronary flow and contractile performance in isolated murine hearts. A 1 KO hearts demonstrate impaired tolerance to ischemia-reperfusion as evidenced by worsened postischemic developed and diastolic pressures, decreased coronary vasodilation throughout reperfusion, and increased tissue injury compared with WT hearts. Targeted deletion of A 1 ARs did not alter expression of A 2A , A 2B , or A 3 adenosine receptors in uninstrumented hearts. The profile of cardiac adenosine receptor expression is changed by ischemiareperfusion with notable induction of adenosine A 2B receptor transcript in both isolated WT and A 1 KO hearts. Together, these data affirm the cardioprotective role of A 1 ARs and suggest that induced expression of other adenosine receptor subtypes participates in the response to ischemia-reperfusion in isolated murine hearts. Ongoing work with this A 1 KO model is needed to delineate the role of A 1 ARs in the in vivo response to ischemia-reperfusion. Determining the receptor-specific effects of adenosine within the cardiovascular system remains an essential step in developing adenosinergic therapies for the clinical management of heart disease.
